Axsome Therapeutics (AXSM) Cash from Investing Activities Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -114.28% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 826.39% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -674.01% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -166.24% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -122.45% |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | 64.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.20% |
| Dec 31, 2025 | -136.67% |
| Sep 30, 2025 | 35.56% |
| Jun 30, 2025 | 75.00% |
| Mar 31, 2025 | -244.90% |
| Dec 31, 2024 | -328.57% |
| Sep 30, 2024 | 75.74% |
| Jun 30, 2024 | 60.90% |
| Mar 31, 2024 | -38.03% |
| Dec 31, 2023 | 96.13% |
| Sep 30, 2023 | -462.12% |
| Jun 30, 2023 | 99.75% |
| Mar 31, 2023 | 66.82% |
| Dec 31, 2022 | -40,033.04% |
| Sep 30, 2022 | 74.49% |
| Jun 30, 2022 | -281,941.64% |
| Mar 31, 2022 | -613.45% |
| Dec 31, 2021 | 97.78% |
| Sep 30, 2021 | -1,642.52% |
| Jun 30, 2021 | -1,221.92% |
| Mar 31, 2021 | -221.46% |
| Dec 31, 2020 | -1,288.57% |
| Sep 30, 2020 | -364.49% |
| Sep 30, 2019 | 62.32% |
| Sep 30, 2018 | -135.39% |
| Jun 30, 2018 | -183.92% |
| Mar 31, 2018 | -402.79% |
| Dec 31, 2017 | 99.98% |
| Sep 30, 2017 | 95.28% |
| Jun 30, 2017 | 70.74% |
| Mar 31, 2017 | 72.78% |
| Dec 31, 2016 | -47.25% |
| Sep 30, 2016 | -1,630.29% |
| Jun 30, 2016 | -716.97% |
| Mar 31, 2016 | -3.85% |